Acuitas Therapeutics to Present Data on Latest LNP Safety and Activity Profiles at ASGCT 2025
VANCOUVER, BC – Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems for the acceleration of partners’ clinical development, announced two poster presentations and one oral presentation highlighting the company’s latest research on enhanced LNP delivery mechanisms and safety profiles across several preclinical models. Presentations will be held at the 2025 American Society of Gene & Cell Therapy’s (ASGCT) Annual General Meeting from May 13 – 17, 2025, in New Orleans.
Acuitas will present new preclinical findings demonstrating the performance of its proprietary LNP formulations across several key metrics, including delivery efficiency, tolerability, safety, and more, from studies conducted in mice and non-human primates. These studies reinforce Acuitas’ commitment to advancing LNP technology through rigorous scientific validation, and to expanding its potential for innovative therapeutic modalities, including CAR T-cell therapies.
Poster Presentations at ASGCT 2025
Title: Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody® Designed Ankyrin Repeat Proteins (DARPins)
- Session Title: Tuesday Poster Reception
- Session Location: Poster Hall I2
- Session Date and Time: May 13, 2025, 6:00 p.m. – 7:30 m.
- Presenter: Ying Tam
Title: Delivery, Potency, and Tolerability of Lipid Nanoparticle Formulations of mRNA in PXB- Mice
- Session Title: Wednesday Poster Reception
- Session Location: Poster Hall I2
- Session Date and Time: May 14, 2025, 5:30 p.m. – 7:00 m.
- Presenter: Merete Eisenhardt
Oral Presentation at ASGCT 2025
Title: Pharmacodynamic Activity, Pharmacokinetics, and Tolerability of Lipid Nanoparticle Formulation of mRNA Following Repeated Intravenous Dosing in Monkeys
- Session Title: Lipid Nanoparticles I
- Session Date and Time: May 15, 2025, 1:30 p.m. – 3:15 m.
- Abstract Presentation Time: 2:45 m. – 3:00 p.m.
- Presenter: Sean Semple
More information about the conference can be found on ASGCT’s website.
About Acuitas Therapeutics, Inc.
Acuitas Therapeutics is a global leader in lipid nanoparticle (LNP) technology and partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutions, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas’ clinically validated LNP technology is applied in Alnylam Pharmaceuticals’ ONPATTRO® for the treatment of transthyretin amyloidosis and the Pfizer- BioNTech COVID-19 vaccine, COMIRNATY®. Current efforts focus on enhancing LNP to advance novel gene therapies, in addition to the identification of potent new lipids to enable partners to develop vaccines for infectious diseases, multivalent vaccines, and novel therapeutic vaccines against cancer, including personalized cancer vaccines.
For more information, visit www.acuitastx.com.
Media Contact:
Jakub Cikowski HDMZ
acuitas.pr@hdmz.com
Original source here.